Vemurafenib: a guide to its use in unresectable or metastatic melanoma

Gillian M Keating, Katherine A Lyseng-Williamson
American Journal of Clinical Dermatology 2013, 14 (1): 65-9
Oral vemurafenib (Zelboraf(®)) is a first-in-class, small molecule BRAF(V600E) inhibitor indicated for the treatment of unresectable or metastatic melanoma in BRAF(V600) mutation-positive patients (EU) or BRAF(V600E) mutation-positive patients (USA). Compared with intravenous dacarbazine, vemurafenib significantly improved overall survival and progression-free survival in patients with unresectable, previously untreated, BRAF(V600E) mutation-positive, stage IIIC or IV melanoma. Oral vemurafenib was generally well tolerated, with cutaneous adverse events among the most commonly occurring adverse events.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"